[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-effector-cell-associated-neurotoxicity-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-effector-cell-associated-neurotoxicity-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,69,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623990","assessing-dcog-short-for-neurotoxicity-in-car-t-100623990",false,"NCT07403812","Assessing DCog Short for Neurotoxicity in CAR-T","Assessing the Performance of \"DCog Short\", an iPad-Based Tool for Neurotoxicity Evaluation in CAR-T Cell Therapy Patients: A Pilot Study","Inclusion Criteria:\n\n* participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.\n* Visual acuity of 20\u002F100 or better.\n\nExclusion Criteria:\n\n* patients \\\u003C 18 years old\n* pregnant women\n* prisoners\n* adults unable to consent,\n* participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.",[26,27,28,29],"Neurotoxicity","Neurotoxicity Syndromes","Hematologic Malignancy","Immune Effector Cell Associated Neurotoxicity Syndrome",[26,31,28,29],"Neurotoxicity Syndrome","NOT_YET_RECRUITING","2026-02-04",{"date":35,"type":36},"2026-02-11","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2027-08-31",{"name":42,"class":43},"Beth Israel Deaconess Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":44},"100622934","multimodal-telerehabilitation-in-patients-undergoing-car-t-cell-immunotherapy-100622934","NCT07390071","Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy","Inclusion Criteria:\n\n* age \\>21\n* confirmed diagnosis of lymphoma or myeloma\n* commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Access to a working telephone line in their home or a cell phone.\n\nExclusion Criteria:\n\n* have unstable angina, uncontrolled hypertension, recent myocardial infarction, pacemakers, painful or unstable bony metastases, or recent skeletal fractures;\n* are engaged in a regular exercise rehabilitation program;\n* have relocation plans within next 6 months;\n* participate in another clinical trial.","21 Years",{"count":19,"type":20},[23],"The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a safe and effective personalized exercise and nutrition plan guided by interactive touch-screen technology combined with behavioral counseling, social support, and interactive education and empowerment. The design of the telerehabilitation system is based on the cloud-based Internet-of-Things architecture allowing real-time monitoring of cardiovascular parameters and exercise performance. The patient's level of exertion during exercise is automatically identified by a validated AI-driven algorithm supporting exercise safety and efficacy. The ultimate goal of this pilot feasibility project is to establish the extent of the impact of the proposed patient-centered cancer telerehabilitation model on disease-specific quality of life, and functional and symptom outcomes and to obtain sufficient evidence for a definitive randomized clinical trial evaluating this approach in a multi-center study.",[56,57,58,29],"Lymphoma","Myeloma","Cytokine Release Syndrome","RECRUITING","2026-01-28",{"date":62,"type":36},"2026-02-05",{"date":64,"type":36},"2025-09-01",{"date":66,"type":20},"2029-01",{"name":68,"class":43},"University of Utah",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":82,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":44},"100570350","phase-4-temporal-characterization-of-extracellular-vesicles-during-cellular-therapy-using-car-t-cells-and-during-the-occurrence-of-immune-effector-cell-associated-neurotoxicity-syndrome-100570350","NCT06706102","Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome","VESICANS","Inclusion Criteria:\n\n* Patient aged over 18,\n* Patient for whom CAR-T treatment is indicated,\n* Patient affiliated to a social security system\n* Patient who give his consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient unable to understand informed consent,\n* Patient under legal protection.",{"count":77,"type":20},60,[79],"PHASE4","Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) is a common and serious neurological complication associated with the use of CAR-T cells. The mechanisms involved are still poorly understood but studies suggest that inflammation during treatment leads to an increase in the permeability of the barrier between the brain and the blood vessels and the emission of extracellular vesicles (EVs) circulating between the brain and the blood vessels. EVs are biological particles that play an important role in cellular communication and the modulation of several physiological processes. The VESICANS study aims to characterize the EVs released before and during CAR-T cells treatment and upon the occurrence of ICANS, using flow cytometry, electron microscopy, Nanoparticle Tracking Analysis associated with MRI assessment of the barrier between the brain and blood. This study will ultimately contribute to facilitating the prevention and treatment of this toxicity which affects the prognosis of patients.",[29],[83,84,85],"CAR-T Cell","ICANS","EVs","2025-07-04",{"date":88,"type":36},"2025-07-09",{"date":90,"type":36},"2025-07-02",{"date":92,"type":20},"2027-11",{"name":94,"class":43},"Centre Hospitalier Universitaire de Saint Etienne",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":104,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":44},"100488667","biomarker-and-imaging-package-study-in-immune-effector-cell-associated-neurotoxicity-syndrome-100488667","NCT05643092","Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome","Inclusion Criteria:\n\n* Subjects must be ≥ 18 years of age at signing of informed consent.\n* Subjects are scheduled to receive CAR T-cell treatment.\n\nExclusion Criteria:\n\n* Refusal to sign the informed consent\n* Subjects having previously been treated with CAR-T therapy.\n* Subjects with clinically significant active bleeding, history of intracranial bleeding, or is at risk for intracranial bleeding\n* Subjects presenting primary CNS lymphoma\n* Pacemaker or other implanted electrical device incompatible with the MR environment\n* Subjects with a neurodegenerative disease (PD, AD)\n* Subjects with a previous or evolving neurological pathology\n* Pregnant or breastfeeding women","80 Years",{"count":103,"type":20},50,"OBSERVATIONAL","CAR T-cell therapy is a promising innovative therapy for hematological malignancies. Immune effectors cells-associated neurotoxicity syndrome (ICANS) is a significant complication of CAR therapy. The goal of this study is to understand what brain mechanisms become disrupted when patients experience ICANS. The study will test the hypothesis that cerebrospinal fluid catecholamines and multimodal magnetic resonance imaging are affected in this disorder.\n\nTo test this hypothesis, the study will measure cerebrospinal fluid catecholamines in ICANS patients and evaluate brain magnetic resonance imaging for these participants. This study may contribute to knowledge about brain biomarkers and imaging of ICANS, which will greatly aid in ICANS detection and prevention.",[29],"2023-03-05",{"date":109,"type":36},"2023-03-07",{"date":111,"type":36},"2023-03-06",{"date":113,"type":20},"2027-12",{"name":115,"class":43},"zhang shoulong"]